Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

@article{Crawford2018AndrogenRT,
  title={Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens},
  author={David E. Crawford and Paul Schellhammer and David G. Mcleod and Judd W. Moul and Celestia S. Higano and Neal D. Shore and Louis J. Denis and Peter Iversen and Mario A. Eisenberger and Fernand Labrie},
  journal={The Journal of Urology},
  year={2018},
  volume={200},
  pages={956–966}
}

Figures from this paper

Second generation androgen receptor antagonists and challenges in prostate cancer treatment

The current state of AR antagonist development is summarized and the emerging challenges of their clinical application and the potential resistance mechanisms are highlighted, which might be addressed by combination therapies or the development of novel AR-targeted therapies.

Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer

Treatment of advanced PCa should be personalized, with administration of a combination of androgen deprivation therapy, ARAT agents, and chemotherapy being based on the patient’s safety profile and the risk of side effects.

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?

Simple Summary Biochemical inhibition of male sex hormone function (androgen signaling), also known as androgen deprivation therapy (ADT), for human prostate cancer remains a major treatment strategy

Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective

It is conceivable that eliminating the AR protein in prostate cancer cells is a promising solution to provide a potential curative outcome, and several potent agents that reduce AR protein levels were reported to eliminate xenograft tumor growth in preclinical models via distinct mechanisms.

The development of apalutamide for the treatment of prostate cancer

Apalutamide has become a relevant therapy for patients with nmCRPC and mHSPC for its benefit in delaying metastasis in addition to its improvement of overall survival, without compromising the quality of life.

Efficacy of novel androgen axis inhibitors for the treatment of hormone-sensitive prostate cancer in patients with visceral metastases: a systematic review and meta-analysis

Patients with mHSPC benefit from the combination of NAT with ADT, regardless of the presence or absence of VM, and treatments with improved overall survival in patients with VM when added to ADT included abiraterone acetate.

Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer

Abstract Men treated with androgen deprivation therapy for rising PSA after failed local therapy will often develop castrate resistance, and the appearance of metastases predicts a poor prognosis.
...

References

SHOWING 1-10 OF 54 REFERENCES

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.

Androgen pathway resistance in prostate cancer and therapeutic implications

This review will explore the resistance mechanisms relevant to hormonal agents, such as AR-V7 expression and others, as well as discussing new approaches being developed to treat patients with castration-resistant prostate cancer that take advantage of these new insights.

Androgen receptor: structure, role in prostate cancer and drug discovery

An overview of androgen receptor structure and activity, its actions in prostate cancer, and how structural information and high-throughput screening have been or can be used for drug discovery are provided are provided.

New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens

The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%‐70% as reported by many groups using the previous partial hormonal therapy.

The changing natural history of metastatic prostate cancer.

It is also important to note that the advent of prostate-specific antigen testing caused a stage shift in the disease spectrum, thus leading to earlier interventions and potentially positively impacting survival, and further refinement of the clinical niche for novel therapies in hormone-sensitive and castration-resistant disease is of paramount importance.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

  • D. RathkopfM. Morris H. Scher
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
ARN-509 was safe and well tolerated, displayed dose-proportional pharmacokinetics, and demonstrated pharmacodynamic and antitumor activity across all dose levels tested.

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.

New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

It is indicated that a combined hormonal therapy which neutralizes all androgenic influences on peripheral tissues is of potential benefit in prostatic cancer and should minimize the development of metastases and androgen-resistant cell clones.

Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer

Among men with nonmetastatic castration‐resistant prostate cancer, metastasis‐free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.
...